| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33b011e77b33662b8bf1f2ff2de7b661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0aecd958fd881845c6ebb9d5630b861c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a60a6799623891943c5de7dac67032af |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-30 |
| filingDate |
2018-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abac116277f3870652fe89b2f7abcee3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75e7c18ed59729a2eacb59db91b5faf8 |
| publicationDate |
2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018237140-A1 |
| titleOfInvention |
TOPOISOMERASE INHIBITORS HAVING ANTIBACTERIAL ACTIVITY AND ANTI-CANCER ACTIVITY |
| abstract |
The present invention relates to human type II topoisomerase inhibitors (Top2) which are the backbone of many cancer chemotherapy regimens. Unfortunately, the onset of toxicity severely limits the usefulness of these potent drugs. There is some conservation between the human Top2 and bacterial homologs (DNA gyrase and TopoIV). Thus, the conversion of antibacterial inhibitors of topoisomerase into antineoplastic agents is a strategy for introducing anticancer compounds. The invention relates to the conversion of deoxynybomycin (DNM) from a natural product and a DNA gyrase inhibitor with minimal cytotoxicity to a compound having anticancer activity. Detailed in vitro and cell culture experiments demonstrate that these compounds inhibit Top2 and also act on topoisomerase I. Similar approaches are applicable to other classes of gyrase inhibitors and other antibacterial targets for the discovery of new drugs. cancer. |
| priorityDate |
2017-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |